Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Clinical trial NCT07750158 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07750158
- Sponsor
- Exelixis
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-06
- Primary completion
- 2030-04-05
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.